Table 1

SUDV vaccine candidates that have or are rapidly progressing to human trials as of 15 November 2022

Vaccine nameStudies conductedLead institution
cAd3-EBO S (VRC-EBOADC086-00-VPPhase I clinical trials in Uganda and USA, completed Planning phase II trialSabin Vaccine Institute (NIAID)
ChAdOx1 biEBOVPhase I clinical trials in the UK and Tanzania (currently recruiting)University of Oxford
rVSV SUDV GPPreclinical phase, rapidly preparing for phase I trial and efficacy studiesMSD
Ad26.ZEBOV, MVA-BN-FiloPhase III clinical trial in Sierra Leone, completed
Vaccine approved by the European Medicines Agency (EMA)
Johnson & Johnson
  • *The Johnson & Johnson vaccine is a two-dose regimen with the second dose providing protection against SUDV. The second dose is administered after 56 days of the first dose.1

  • EMA, European Medicines Agency; MSD, Merck; NIAID, National Institute of Allergy and Infectious Diseases; SUDV, Sudan ebolavirus.